Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging

Journal of Neuropathology and Experimental Neurology

Volumn 69, Issue 1, 2010, Pages 98-108

  Silverberg, Gerald D ^a   Miller, Miles C ^a   Messier, Arthur A ^a   Majmudar, Samir ^a   MacHan, Jason T ^a   Donahue, John E ^a   Stopa, Edward G ^a   Johanson, Conrad E ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Aging; Amyloid; Blood brain barrier; RAGE; Transport

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

AGE FACTORS; AGING; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; MALE; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; RATS; RATS, INBRED F344; RECEPTORS, IMMUNOLOGIC;

EID: 74049111316     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181c8ad2f     Document Type: Article

References (63)

1. National Institute of Aging. Alzheimer's Disease Unraveling the Mystery. US Department of Health and Human Services, 2002; NIH Publication Number 02-3782
2. Lu T, Pan Y, Kao SY, et al. Gene regulation and DNA damage in the aging human brain. Nature 2004;429:883-891
3. Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol 2008;3: 41-66
4. Hardy J. A hundred years of Alzheimer's disease research. Neuron 2006; 52:3-13
5. Deane R, Zlokovic BV. Role of blood brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2007;4:191-197
6. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid A-peptide. Nat Rev Mol Cell Biol 2007;8:101-112
7. Rubenstein E. Relationship of senescence of cerebrospinal fluid circulatory system to dementias of the aged. Lancet 1998;351:283-285
8. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid A-protein. Ann NY Acad Sci 2000;924:17-25
9. Trojanowski JQ, Lee V. Brain degeneration linked to Bfatal attractions[ of proteins in Alzheimer's disease and related disorders. J Alzheimers Dis 2001;3:117-19
10. Silverberg GD, Mayo M, Saul T, et al. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: A hypothesis. Lancet Neurol 2003;2:506-511
11. Zlokovic BV, Ghiso J, Mackic JB et al. Blood-brain barrier transport of circulating Alzheimer's amyloid A. Biochem Biophys Res Commun 1993;197:1034-1040
12. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid A-peptide clearance through transport across the blood-brain barrier. Stroke 2004;35(suppl 1):2628-2631
13. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-A1-40 peptide from brain by LDL receptorYrelated protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-1499
14. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-A deposition in an Alzheimer disease mouse model. J Clin Invest 2005;115:3285-3290
15. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid b-peptide across the blood-brain barrier and accumulation in the brain. Nat Med 2003;9:907-913
16. Masters CL, Multhaup G, Simms G, et al. Neuronal origin of a cerebral amyloid: Neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 1985; 4:2757-2763
17. Siman R, Card JP, Nelson RB, et al. Expression of beta-amyloid precursor protein in reactive astrocytes following neuronal damage. Neuron 1989;3: 275-285
18. Vitek MP, Battacharaya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer's disease. Proc Natl Acad Sci U S A 1994;91:4766-4770
19. Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 2006; 112:405-415
20. Miller MC, Taveres R, Johanson CE, et al. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 2008;1230:273-280
21. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-15004
22. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699-1712
23. Ding O, Keller JN. Evaluation of rage isoforms, ligands and signaling in the brain. Biochim Biophys Acta 2005;1746:18-27
24. Schmidt AM, Stern DM. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: Implications for host response mechanisms in homeostasis and chronic disease. Front Biosci 2001;6: D1151-60
25. Casselmann C, Reimann A, Friedrich I, et al. Age-dependent expression of advanced glycation end products receptor genes in the human heart. Gerontology 2004;50:127-134
26. Wautier JL, Schmidt AM. Protein glycation: A firm link to endothelial cell dysfunction. Circ Res 2004;95:233-238
27. Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001;888:256-262
28. Ramasamy R, Vannucci SJ, Du Yan SS, et al. Advanced glycation end products and RAGE: A common thread in aging, diabetes, neuro-degeneration, and inflammation. Glycobiol 2005;15:16R-28R
29. Lin L. RAGE on the Toll road' Cell Mol Immunol 2006;3:351-358
30. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-9897
31. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end-products. J Biol Chem 1997;272:16498-16506
32. Schmidt AM, Hasu M, Popov D, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 1994;91:8807-8811
33. Lohwasser C, Neureiter D, Weigle B, et al. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol 2006;196:291-299
34. Banks WA, Robinson SM, Verma S, et al. Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: Impairment in a mouse model of Alzheimer's disease. Neuroscience 2003;121:487-492
35. Wu LC, D'Amelio F, Fox RA, et al. Light microscopic image analysis system to quantify immunoreactive terminal area apposed to nerve cells. J Neurosci Methods 1997;74:89-96
36. Stopa EG, Butala P, Salloway S, et al. Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype. Stroke 2008;39:814-821
37. 717) mutants. Science 1994;264:336-340
38. Fukumoto H, Tomita T, Matsunaga H, et al. Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid A peptides ending at AA40 and AA42. Neuroreport 1999;10:2965-2969
39. Yousif S, Marie-Claire C, Roux F, et al. Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain micro-vessel strategy. Brain Res 2007;1134:1-11
40. Silverberg GD, Heit G, Huhn S, et al. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology 2001;57: 1763-1766
41. Deane R, Sagare A, Hamm K, et al. ApoE isoformYspecific disruption of amyloid A peptide clearance from mouse brain. J Clin Invest 2008;118: 4002-4013
42. Davson H, Oldendorf WH. Symposium on membrane transport. Transport in the central nervous system. Proc R Soc Med 1967;60:326-329
43. Weller RO. Pathology of cerebrospinal fluid and interstitial fluid of the CNS: Significance for Alzheimer's disease, prion disorders and multiple sclerosis. J Neuropathol Exp Neurol 1998;57:885-894
44. Iwata N, Tsubuki S, Takaki Y, et al. Identification of the major Abeta1-42Y degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med 2000;6:143-150
45. Preston JE. Aging choroid plexusYcerebrospinal system. Microsc Res Tech 2001;52:31-37
46. Head E, Moffat K, Das P, et al. Beta-amyloid deposition and tau phosphorylation in clinically characterized aged cats. Neurobiol Aging 2005;26:749-763
47. Vaucher E, Aumont N, Pearson D, et al. Amyloid beta peptide levels and its effect on hippocampal acetylcholine release in aged, cognitively-impaired and-unimpaired rats. J Chem Neuroanat 2001;21:323-329
48. Banks WA, Farr SA, Morley JE, et al. Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: An age-related selective uptake with reversal of learning impairment. Exp Neurol 2007;206:248-256
49. Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia. Ann Neurol 1988;23:138-144
50. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259
51. Braak H, Braak E. Demonstration of amyloid deposits and neuro-fibrillary changes in whole brain sections. Brain Pathol 1991;1:213-216
52. Price J, Davis P, Morris J, White D. The distribution of tangles, plaques, and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991;12:295-312
53. Arriagada P, Marzloff K, Hyman B. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992;42:1681-1688
54. Giannakopoulos P, Hof P, Giannakopoulos AS, Herrmann F, Michel JP, Bouras C. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of very old patients. Arch Neurol 1995;52: 1150-1160
55. Davis D, Schmitt F, Wekstein D, Markesbery W. Alzheimer neuro-pathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999;58:376-388
56. Bell RD, Sagare AP, Friedman AE, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipopro-teins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2006;27:909-918
57. Silverberg GD, Caralopoulos IN, Slone SL, et al. Amyloid and Tau accumulation precede CSF production decline in normal aging [Abstract]. CSF Res 2009;6(suppl 1):S38.
58. White FP, Dutton GR, Norenberg MD. Microvessels isolated from rat brain: Localization of astrocyte processes by immunohistochemical techniques. J Neurochem 1981;36:328-332
59. Moro V, Kacem K, Springhetti V, et al. Microvessels isolated from brain: Localization of muscarinic sites by radioligand binding and immuno-fluorescent techniques. J Cereb Blood Flow Metab 1995;15:1082-1092
60. Hickman SE, Allison EK, El Koury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008;28:8354-8360
61. Leclerc E, Fritz G, Weibel M, et al. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem 2007;282:31317-31331
62. Schmidt AM, Wautier J-L, Stern D, et al. RAGE: A receptor with a taste for multiple ligands and varied pathophysiologic states. In: O'Malley BW, ed. Hormones and Signaling. Amsterdam, Holland: Elsevier Inc, 1998;41-63
63. Tohgi H, Utsugisawa K, Nagane Y, et al. Decrease with age in methylcytosines in the promoter region of receptor for advanced glycation end products (RAGE) gene in autopsy human cortex. Brain Res Mol Brain Res 1999;65:124-128